Role of synovial fibroblasts in rheumatoid arthritis

Current Pharmaceutical Design

Volumn 21, Issue 2, 2015, Pages 130-141

  Lefevre S ^a   Meier, F M P ^a   Neumann, E ^a   Muller Ladner U ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Activation; Cytokines; Epigenetics; Migration; Rheumatoid arthritis; Synovial fibroblast; TLR

Indexed keywords

ADIPOCYTOKINE; AUTOANTIBODY; AUTOANTIGEN; CADHERIN; CHEMOKINE; CYTOKINE; GROWTH FACTOR; INTEGRIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MICRORNA; TISSUE INHIBITOR OF METALLOPROTEINASE; TOLL LIKE RECEPTOR;

ACETYLATION; ARTICLE; ARTICULAR CARTILAGE; B LYMPHOCYTE; BONE DEFECT; CARTILAGE CELL; CARTILAGE DEGENERATION; CELL INTERACTION; CELL MIGRATION; CYTOPATHOLOGY; DISEASE COURSE; DNA METHYLATION; EPIGENETICS; FIBROBLAST; HUMAN; INNATE IMMUNITY; INTRACELLULAR SIGNALING; MACROPHAGE; NONHUMAN; OSTEOCLAST; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; SYNOVITIS; SYNOVIUM; T LYMPHOCYTE; CELL ADHESION; IMMUNOLOGY; PATHOLOGY;

ARTHRITIS, RHEUMATOID; CELL ADHESION; FIBROBLASTS; HUMANS; IMMUNITY, INNATE; SYNOVIAL MEMBRANE;

EID: 84922989258     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140825122036     Document Type: Article

References (160)

1. Müller-Ladner U, Ospelt C, Gay S, Distler O, Pap T. Cells of the synovium in rheumatoid arthritis. Synovial fibroblasts. Arthritis Res Ther 2007; 9: 223.
2. Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 2010; 233: 233-55.
3. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365: 2205-19.
4. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007; 7: 429-42.
5. Kochi Y, Suzuki A, Yamada R, Yamamoto K. Ethnogenetic heterogeneity of rheumatoid arthritis-implications for pathogenesis. Nat Rev Rheumatol 2010; 6: 290-5.
6. Padyukov L, Silva C, Stolt P, Alfredsson L, Klareskog L. A geneenvironment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum 2004; 50: 3085-92.
7. Holoshitz J. The rheumatoid arthritis HLA-DRB1 shared epitope. Curr Opin Rheumatol 2010; 22: 293-8.
8. Ma Y, Pope RM. The role of macrophages in rheumatoid arthritis. Curr Pharm Des 2005; 11: 569-580.
9. Gravallese EM. Bone destruction in arthritis. Ann Rheum Dis 2002; 61: ii84-ii86.
10. Yasuda T. Cartilage destruction by matrix degradation products. Mod Rheumatol 2006; 16: 197-205.
11. Skapenko A, Leipe J, Lipsky PE, Schulze-Koops H. The role of the T cell in autoimmune inflammation. Arthritis Res Ther 2005; 7: S4-14.
12. Szekanecz Z, Besenyei T, Paragh G, Koch AE. New insights in synovial angiogenesis. Joint Bone Spine 2010; 77: 13-9.
13. Müller-Ladner U, Kriegsmann J, Franklin BN, et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 1996; 149: 1607-15.
14. van Beurden HE, Snoek PA, Von den Hoff JW, Torensma R, Kuijpers- Jagtman AM. Fibroblast subpopulations in intra-oral wound healing. Wound Repair Regen 2003; 11: 55-63.
15. Huber LC, Distler O, Tarner I, Gay RE, Gay S, Pap T. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology 2006; 45: 669-75.
16. Lowin T, Straub RH, Neumann E, et al. Glucocorticoids increase alpha5 integrin expression and adhesion of synovial fibroblasts but inhibit ERK signaling, migration, and cartilage invasion. Arthritis Rheum 2009; 60: 3623-32.
17. Neumann E, Lefèvre S, Zimmermann B, Gay S, Müller-Ladner U. Rheumatoid arthritis progression is mediated by activated synovial fibroblasts. Trends Mol Med 2010; 16: 458-68.
18. McGettrick HM, Smith E, Filer A, et al. Fibroblasts from different sites may promote or inhibit recruitment of flowing lymphocytes by endothelial cells. Eur J Immunol 2009; 39: 113-25.
19. Filer A, Parsonage G, Smith E, et al. Differential survival of leukocyte subsets mediated by synovial, bone marrow, and skin fibroblasts: site-specific versus activation-dependent survival of T cells and neutrophils. Arthritis Rheum 2006; 54: 2096-108.
20. Ohata J, Zvaifler NJ, Nishio M, et al. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 2005; 174: 864-70.
21. Cha HS, Rosengren S, Boyle DL, Firestein GS. PUMA regulation and proapoptotic effects in fibroblast-like synoviocytes. Arthritis Rheum 2006; 54: 587-92.
22. Woods JM, Klosowska K, Spoden DJ, et al. A cell-cycle independent role for p21 in regulating synovial fibroblast migration in rheumatoid arthritis. Arthritis Res Ther 2006; 8: R113.
23. Korb A, Pavenstädt H, Pap T. Cell death in rheumatoid arthritis. Apoptosis 2009; 14: 447-54.
24. Seibl R, Birchler T, Loeliger S, et al. Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. Am J Pathol 2003; 162: 1221-7.
25. Ospelt C, Brentano F, Rengel Y, et al. Overexpression of Toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis. Arthritis Rheum 2008; 58: 3684-92.
26. Goh FG, Midwood KS. Intrinsic danger: activation of Toll-like receptors in rheumatoid arthritis. Rheumatology 2012; 51: 7-23.
27. Sacre SM, Andreakos E, Kiriakidis S, et al. The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis. Am J Pathol 2007; 170: 518-25.
28. Brentano F, Kyburz D, Gay S. Toll-like receptors and rheumatoid arthritis. Methods Mol Biol 2009; 517: 329-43.
29. Maciejewska-Rodrigues H, Jüngel A, Gay RE, Gay S. Innate immunity, epigenetics and autoimmunity in rheumatoid arthritis. Mol Immunol 2009; 47: 12-8.
30. Kim KW, Cho ML, Lee SH, et al. Human rheumatoid synovial fibroblasts promote osteoclastogenic activity by activating RANKL via TLR-2 and TLR-4 activation. Immunol Lett 2007; 110: 54-64.
31. Wu CY, Chi PL, Hsieh HL, Luo SF, Yang CM. TLR4-dependent induction of vascular adhesion molecule-1 in rheumatoid arthritis synovial fibroblasts: roles of cytosolic phospholipase A(2)alpha/cyclooxygenase-2. J Cell Physiol 2010; 223: 480-91.
32. Kim KW, Cho ML, Oh HJ, et al. TLR-3 enhances osteoclastogenesis through upregulation of RANKL expression from fibroblast-like synoviocytes in patients with rheumatoid arthritis. Immunol Lett 2009; 124: 9-17.
33. Ostuni R, Zanoni I, Granucci F. Deciphering the complexity of Toll-like receptor signaling. Cell Mol Life Sci 2010; 67: 4109-34.
34. Foell D, Wittkowski H, Roth J. Mechanisms of disease: a’DAMP’ view of inflammatory arthritis. Nat Clin Pract Rheumatol 2007; 3: 382-90.
35. Midwood K, Sacre S, Piccinini AM, et al. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 2009; 15: 774-80.
36. Brentano F, Schorr O, Gay RE, Gay S, Kyburz D. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum 2005; 52: 2656-65.
37. Cho ML, Ju JH, Kim HR, et al. Toll-like receptor 2 ligand mediates the upregulation of angiogenic factor, vascular endothelial growth factor and interleukin-8/CXCL8 in human rheumatoid synovial fibroblasts. Immunol Lett 2007; 108: 121-8.
38. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388: 394-7.
39. Mahdi H, Fisher BA, Källberg H, et al. Specific interaction between genotype, smoking and autoimmunity to citrullinated alphaenolase in the etiology of rheumatoid arthritis. Nat Genet 2009; 41: 1319-24.
40. van der Woude D, Rantapää-Dahlqvist S, Ioan-Facsinay A, et al. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis 2010; 69: 1554-61.
41. Sanchez-Pernaute O, Filkova M, Gabucio A, et al. Citrullination enhances the pro-inflammatory response to fibrin in rheumatoid arthritis synovial fibroblasts. Ann Rheum Dis 2013; 72: 1400-6.
42. Sacre S, Medghalchi M, Gregory B, Brennan F, Williams R. Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. Arthritis Rheum 2010; 62: 683-93.
43. Vanags D, Williams B, Johnson B, et al. Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial. Lancet 2006; 368: 855-63.
44. Ultaigh SN, Saber TP, McCormick J, et al. Blockade of Toll-like receptor 2 prevents spontaneous cytokine release from rheumatoid arthritis ex vivo synovial explant cultures. Arthritis Res Ther 2011; 13: R33.
45. Arslan F, Houtgraaf JH, Keogh B, et al. Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs. Circ Cardiovasc Interv 2012; 5: 279-87.
46. O’Neill LA, Sheedy FJ, McCoy CE. MicroRNAs: the fine-tuners of Toll-like receptor signaling. Nat Rev Immunol 2011; 11: 163-75.
47. Philippe L, Alsaleh G, Suffert G, et al. TLR2 expression is regulated by microRNA miR-19 in rheumatoid fibroblast-like synoviocytes. J Immunol 2012; 188: 454-61.
48. Gibbons LJ, Hyrich KL. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response. Bio Drugs 2009; 23: 111-24.
49. Neumann E, Riepl B, Knedla A, et al. Cell culture and passaging alters gene expression pattern and proliferation rate in rheumatoid arthritis synovial fibroblasts. Arthritis Res Ther 2010; 12: R83.
50. Benito-Miguel M, García-Carmona Y, Balsa A, et al. IL-15 expression on RA synovial fibroblasts promotes B cell survival. PLoS One 2012; 7: e40620.
51. Page CE, Smale S, Carty SM, et al. Interferon-gamma inhibits interleukin-1beta-induced matrix metalloproteinase production by synovial fibroblasts and protects articular cartilage in early arthritis. Arthritis Res Ther 2010; 12: R49.
52. Kato H, Endres J, Fox DA. The roles of IFN- γ versus IL-17 in pathogenic effects of human Th17 cells on synovial fibroblasts. Mod Rheumatol 2013; 23: 1140-50.
53. Honorati MC, Neri S, Cattini L, Facchini A. Interleukin-17, a regulator of angiogenic factor release by synovial fibroblasts. Osteoarthritis Cartilage 2006, 14: 345-52.
54. Volin MV, Koch AE. Interleukin-18: a mediator of inflammation and angiogenesis in humanoid arthritis. J Interferon Cytokine Res 2011; 31: 745-51.
55. Tanida S, Yoshitomi H, Ishikawa M, et al. IL-27-producing CD14(+) cells infiltrate inflamed joints of rheumatoid arthritis and regulate inflammation and chemotactic migration. Cytokine 2011; 55: 237-44.
56. Heinhuis B, Koenders MI, van Riel PL, et al. Tumour necrosis factor alpha-driven IL-32 expression in rheumatoid arthritis synovial tissue amplifies an inflammatory cascade. Ann Rheum Dis 2011; 70: 660-7.
57. Alsaleh G, Sparsa L, Chatelus E, et al. Innate immunity triggers IL- 32 expression by fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Res Ther 2010; 12: R135.
58. Kakkar R, Hei H, Dobner S, Lee RT. Interleukin 33 as a mechanically responsive cytokine secreted by living cells. J Biol Chem 2012; 287: 6941-8.
59. Kunisch E, Chakilam S, Gandesiri M, Kinne RW. IL-33 regulates TNF-dependent effects in synovial fibroblasts. Int J Mol Med 2012; 29: 530-40.
60. Malemud CJ. Growth hormone, VEGF and FGF: involvement in rheumatoid arthritis. Clin Chim Acta 2007; 375: 10-9.
61. Nakano K, Okada Y, Saito K, Tanaka Y. Induction of RANKL expression and osteoclast maturation by the binding of fibroblast growth factor 2 to heparan sulfate proteoglycan on rheumatoid synovial fibroblasts. Arthritis Rheum 2004; 50: 2450-8.
62. Del Rey MJ, Izquierdo E, Usategui A, et al. The transcriptional response of normal and rheumatoid arthritis synovial fibroblasts to hypoxia. Arthritis Rheum 2010; 62: 3584-94.
63. Raychaudhuri SP, Raychaudhuri SK, Atkuri KR, Herzenberg LA, Herzenberg LA. Nerve growth factor: A key local regulator in the pathogenesis of inflammatory arthritis. Arthritis Rheum 2011; 63: 3243-52.
64. Rico MC, Rough JJ, Del Carpio-Cano FE, Kunapuli SP, DeLa Cadena RA. The axis of thrombospondin-1, transforming growth factor beta and connective tissue growth factor: an emerging therapeutic target in rheumatoid arthritis. Curr Vasc Pharmacol 2010; 8: 338-43.
65. Cho ML, Min SY, Chang SH, et al. Transforming growth factor beta 1(TGF-beta1) down-regulates TNFalpha-induced RANTES production in rheumatoid synovial fibroblasts through NF-kappaBmediated transcriptional repression. Immunol Lett 2006, 105: 159- 66.
66. Pohlers D, Huber R, Ukena B, Kinne RW. Expression of plateletderived growth factors C and D in the synovial membrane of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum 2006; 54: 788-94.
67. Rosengren S, Corr M, Boyle DL. Platelet-derived growth factor and transforming growth factor beta synergistically potentiate inflammatory mediator synthesis by fibroblast-like synoviocytes. Arthritis Res Ther 2010; 12: R65.
68. Terabe F, Kitano M, Kawai M, et al. Imatinib mesylate inhibited rat adjuvant arthritis and PDGF-dependent growth of synovial fibroblast via interference with the Akt signaling pathway. Mod Rheumatol 2009; 19: 522-9.
69. Neumann E, Frommer KW, Vasile M, Müller-Ladner U. Adipocytokines as driving forces in rheumatoid arthritis and related inflammatory diseases? Arthritis Rheum 2011; 63: 1159-69.
70. Frommer KW, Zimmermann B, Meier FM, et al. Adiponectinmediated changes in effector cells involved in the pathophysiology of rheumatoid arthritis. Arthritis Rheum 2010; 62: 2886-99.
71. Lee YA, Choi HM, Lee SH, et al. Synergy between adiponectin and interleukin-1_ on the expression of interleukin-6, interleukin-8, and cyclooxygenase-2 in fibroblast-like synoviocytes. Exp Mol Med 2012; 44: 440-7.
72. Ehling A, Schäffler A, Herfarth H, et al. The potential of adiponectin in driving arthritis. J Immunol 2006; 176: 4468-78.
73. Frommer KW, Schäffler A, Büchler C, et al. Adiponectin isoforms: a potential therapeutic target in rheumatoid arthritis? Ann Rheum Dis 2012; 71: 1724-32.
74. Brentano F, Schorr O, Ospelt C, et al. Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum 2007; 56: 2829-39.
75. Busso N, Karababa M, Nobile M, et al. Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PloS One 2008; 3: e2267.
76. Meier FM, Frommer KW, Peters MA, et al. Visfatin/pre-B-cell colony-enhancing factor (PBEF), a proinflammatory and cellmotility- changing factor in rheumatoid arthritis. J Biol Chem 2012; 287: 28378-85.
77. Eisinger K, Bauer S, Schäffler A, et al. Chemerin induces CCL2 and TLR4 in synovial fibroblasts of patients with rheumatoid arthritis and osteoarthritis. Exp Mol Pathol 2012; 92: 90-6.
78. Chen HT, Tsou HK, Hsu CJ, et al. Stromal cell-derived factor- 1/CXCR4 promotes IL-6 production in human synovial fibroblasts. J Cell Biochem 2011; 112: 1219-27.
79. Georganas C, Liu H, Perlman H, Hoffmann A, Thimmapaya B, Pope RM. Regulation of IL-6 and IL-8 expression in rheumatoid arthritis synovial fibroblasts: the dominant role for NF-B but not C/EBP _ or c-Jun. J Immunol 2000; 165: 7199-206.
80. Nanki T, Nagasaka K, Hayashida K, Saita Y, Miyasaka N. Chemokines regulate IL-6 and IL-8 production by fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Immunol 2001; 167: 5381-5.
81. Murphy G, Caplice N, Molloy M. Fractalkine in rheumatoid arthritis: a review to date. Rheumatology 2008; 47: 1446-51.
82. Guo X, Pan Y, Xiao C, Wu Y, Cai D, Gu J. Fractalkine stimulates cell growth and increases its expression via NF-κB pathway in RAFLS. Int J Rheum Dis 2012; 15: 322-9.
83. Brühl H, Mack M, Niedermeier M, Lochbaum D, Schölmerich J, Straub RH. Functional expression of the chemokine receptor CCR7 on fibroblast-like synoviocytes. Rheumatology 2008; 47: 1771-4.
84. Pickens SR, Chamberlain ND, Volin MV, Pope RM, Mandelin AM 2nd, Shahrara S. Characterization of CCL19 and CCL21 in rheumatoid arthritis. Arthritis Rheum 2011; 63: 914-22.
85. Koch AE. Chemokines and their receptors in rheumatoid arthritis: future targets? Arthritis Rheum 2005; 52: 710-21.
86. Laragione T, Brenner M, Sherry B, Gulko PS. CXCL10 and its receptor CXCR3 regulate synovial fibroblast invasion in rheumatoid arthritis. Arthritis Rheum 2011; 63: 3274-3283.
87. Bird A. Perceptions of epigenetics. Nature 2007; 447: 396-8.
88. Goll MG, Bestor TH. Eukaryotic cytosine methyltransferases. Annu Rev Biochem 2005; 74: 481-514.
89. Karouzakis E, Gay RE, Michel BA, Gay S, Neidhart M. DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2009; 60: 3613-22.
90. Karouzakis E, Gay RE, Gay S, Neidhart M. Increased recycling of polyamines is associated with global DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2012; 64: 1809-17.
91. Nakano K, Boyle DL, Firestein GS. Regulation of DNA methylation in rheumatoid arthritis synoviocytes. J Immunol 2013; 190: 1297-303.
92. Nakano K, Whitaker JW, Boyle DL, Wang W, Firestein GS. DNA methylome signature in rheumatoid arthritis. Ann Rheum Dis 2013; 72: 110-7.
93. Karouzakis E, Rengel Y, Jüngel A, et al. DNA methylation regulates the expression of CXCL12 in rheumatoid arthritis synovial fibroblasts. Genes Immun 2011; 12: 643-52.
94. Huber LC, Brock M, Hemmatazad H, et al. Histone deacetylase/ acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients. Arthritis Rheum 2007; 56: 1087-93.
95. Choo QY, Ho PC, Tanaka Y, Lin HS. Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-kappaB p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells. Rheumatology 2010; 49: 1447-60.
96. Jüngel A, Baresova V, Ospelt C, et al. Trichostatin A sensitizes rheumatoid arthritis synovial fibroblasts for TRAIL-induced apoptosis. Ann Rheum Dis 2006; 65: 910-2.
97. Nasu Y, Nishida K, Miyazawa S, et al. Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. Osteoarthritis Cartilage 2008; 16: 723-32.
98. Grabiec AM, Tak PP, Reedquist KA. Function of histone deacetylase inhibitors in inflammation. Crit Rev Immunol 2011; 31: 233-63.
99. Grabiec AM, Korchynskyi O, Tak PP, Reedquist KA. Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. Ann Rheum Dis 2012; 71: 424-31.
100. Montgomery RL, van Rooij E. MicroRNA regulation as a therapeutic strategy for cardiovascular disease. Curr Drug Targets 2010; 11: 936-42.
101. Baltimore D, Boldin MP, O’ Connell RM, Rao DS, Taganov KD. MicroRNAs: new regulators of immune cell development and function. Nat Immunol 2008; 90: 839-45.
102. Mudhasani R, Zhu Z, Hutvagner G, et al. Loss of miRNA biogenesis induces p19Arf-p53 signaling and senescence in primary cells. J Cell Biol 2008; 181: 1055-63.
103. Tili E, Michaille JJ, Costinean S, Croce CM. MicroRNAs, the immune system and rheumatic disease. Nat Clin Pract Rheumatol 2008: 4: 534-41.
104. Amman M, Jorgensen C, Apparailly F. Impact of microRNAs on the understanding and treatment of rheumatoid arthritis. Curr Opin Rheumatol 2013; 25: 225-33.
105. Stanczyk J, Pedrioli DM, Brentano F, et al. Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum 2008; 58: 1001-9.
106. Nakasa T, Miyaki S, Okubo A, et al. Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum 2008; 58: 1284-92.
107. Nakasa T, Shibuya H, Nagata Y, Niimoto T, Ochi M. The inhibitory effect of microRNA-146a expression on bone destruction in collagen-induced arthritis. Arthritis Rheum 2011; 63: 1582-90.
108. Kurowska-Stolarska M, Alivernini S, Ballantine LE, Asquith DL, Millar NL, Gilchrist DS, et al. MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. PNAS 2011; 108: 11193-8.
109. Stanczyk J, Ospelt C, Karouzakis E, et al. Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation. Arthritis Rheum 2011; 63: 373-81.
110. Nakamachi Y, Kawano S, Takenokuchi MM, et al. MicroRNA- 124a is a key regulator of proliferation and monocyte chemoattractant protein 1 secretion in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum 2009; 60: 1294-304.
111. Niederer F, Trenkmann F, Ospelt C, et al. Down-regulation of microRNA-34a* in rheumatoid arthritis synovial fibroblasts promotes apoptosis resistance. Arthritis Rheum 2012; 64: 1771-9.
112. Trenkmann M, Brock M, Gay RE, Michel BA, Gay S, Huber LC. Tumor necrosis factor -induced microRNA-18a activates rheumatoid arthritis synovial fibroblasts through a feedback loop in NF-B signaling. Arthritis Rheum 2013; 65: 916-27.
113. De la Rica L, Urquiza JM, Gómez-Cabrero D, et al. Identification of novel markers in rheumatoid arthritis through integrated analysis of DNA methylation and microRNA expression. J Autoimmun 2013; 41: 6-16.
114. Distler JH, Pisetsky DS, Huber LC, Kalden JR, Gay S, Distler O. Microparticles as regulators of inflammation: novel players of cellular crosstalk in the rheumatic diseases. Arthritis Rheum 2005; 52: 3337-48.
115. Beyer C, Pisetsky DS. The role of microparticles in the pathogenesis of rheumatic diseases. Nat Rev Rheumatol 2010; 6: 21-9.
116. György B, Szabo TG, Pasztoi M, et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci 2011; 68: 2667-88.
117. Boilard E, Blanco P, Nigrovic PA. Platelets: active players in the pathogenesis of arthritis and SLE. Nat Rev Rheumatol 2012; 8: 534-42.
118. Messer L, Alsaleh G, Freyssinet JM, et al. Microparticle-induced release of B-lymphocyte regulators by rheumatoid synoviocytes. Arthritis Res Ther 2009; 11: R40.
119. Burger D, Schock S, Thompson CS, Montezano AC, Hakim AM, Touyz RM. Microparticles: biomarkers and beyond. Clin Sci 2013; 124: 423-41.
120. Cloutier N, Tan S, Boudreau LH, et al. The exposure of autoantigens by microparticles underlies the formation of potent inflammatory components: the microparticle-associated immune complexes. EMBO Mol Med 2013; 5: 235-49.
121. Lefèvre S, Knedla A, Tennie C, et al. Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat Med 2009; 15: 1414-20.
122. Peters MA, Wendholt D, Strietholt S, et al. The loss of 21 integrin suppresses joint inflammation and cartilage destruction in mouse models of rheumatoid arthritis. Arthritis Rheum 2012; 64: 1359-68.
123. Kitagawa A, Miura Y, Saura R, et al. Anchorage on fibronectin via VLA-5 (alpha5beta1 integrin) protects rheumatoid synovial cells from Fas-induced apoptosis. Ann Rheum Dis 2006, 65: 721-7.
124. Lee DM. Cadherin-11 in synovial lining formation and pathology in arthritis. Science 2007; 315: 1006-10.
125. Noss EH, Chang SK, Watts GF, Brenner MB. Modulation of matrix metalloproteinase production by rheumatoid arthritis synovial fibroblasts after cadherin 11 engagement. Arthritis Rheum 2011; 63: 3768-78.
126. Chang SK, Noss EH, Chen M, et al. Cadherin-11 regulates fibroblast inflammation. PNAS 2011; 108: 8402-7.
127. Cunnane G, FitzGerald O, Hummel K, Gay RE, Gay S, Bresnihan B. Collagenase, cathepsin B and cathepsin L gene expression in the synovial membrane of patients with early inflammatory arthritis. Rheumatology 1999; 38: 34-43.
128. Cha HS, Ahn KS, Jeon CH, Kim J, Song YW, Koh EM. Influence of hypoxia on the expression of matrix metalloproteinase-1, -3 and tissue inhibitor of metalloproteinase-1 in rheumatoid synovial fibroblasts. Clin Exp Rheumatol 2003; 21: 593-8.
129. Kyburz D, Rethage J, Seibl R, et al. Bacterial peptidoglycans but not CpG oligodeoxynucleotides activate synovial fibroblasts by toll-like receptor signaling. Arthritis Rheum 2003; 48: 642-50.
130. Su J, Yu J, Ren T, Zhang W, Zhang Y, Liu X. Discoidin domain receptor 2 is associated with the increased expression of matrix metalloproteinase-13 in synovial fibroblasts of rheumatoid arthritis. Mol Cell Biochem 2009; 330: 141-52.
131. Frank S, Peters MA, Wehmeyer C, et al. Regulation of matrixmetalloproteinase- 3 and matrixmetalloproteinase-13 by SUMO-2/3 through the transcription factor NF-_B. Ann Rheum Dis 2013; 72: 1874-81.
132. Maciejewska-Rodrigues H, Karouzakis E, Strietholt S, et al. Epigenetics and rheumatoid arthritis: the role of SENP1 in the regulation of MMP-1 expression. J Autoimmun 2010; 35: 15-22.
133. Rutkauskaite E, Zacharias W, Schedel J, et al. Ribozymes that inhibit the production of matrix metalloproteinase 1 reduce the invasiveness of rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2004; 50: 1448-56.
134. Sabeh F, Fox D, Weiss SJ. Membrane-type I matrix metalloproteinase- dependent regulation of rheumatoid arthritis synoviocyte function. J Immunol 2010; 184: 6396-406.
135. Miller MC, Manning HB, Jain A, et al. Membrane type 1 matrix metalloproteinase is a crucial promoter of synovial invasion in rheumatoid arthritis. Arthritis Rheum 2009; 60: 686-97.
136. Green MJ, Gough AK, Devlin J, et al. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology 2003; 42: 83-8.
137. Kobayashi A, Naito S, Enomoto H, et al. Serum levels of matrix metalloproteinase 3 (stromelysin 1) for monitoring synovitis in rheumatoid arthritis. Arch Pathol Lab Med 2007; 131: 563-70.
138. Schedel J, Seemayer CA, Pap T, et al. Targeting cathepsin L (CL) by specific ribozymes decreases CL protein synthesis and cartilage destruction in rheumatoid arthritis. Gene Ther 2004; 11: 1040-7.
139. Salminen-Mankonen HJ, Morko J, Vuorio E. Role of cathepsin K in normal joints and in the development of arthritis. Curr Drug Targets 2007; 8: 315-23.
140. Hashizume M, Hayakawa N, Suzuki M, Mihara M. IL-6/sIL-6R trans-signalling, but not TNF-alpha induced angiogenesis in a HUVEC and synovial cell co-culture system. Rheumatol Int 2009; 29: 1449-54.
141. van der Laan WH, Quax PH, Seemayer CA, et al. Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3. Gene Ther 2003, 10: 234-42.
142. García-Vicuña R, Gómez-Gaviro MV, Domínguez-Luis MJ, et al. CC and CXC chemokine receptors mediate migration, proliferation, and matrix metalloproteinase production by fibroblast-like synoviocytes from rheumatoid arthritis patients. Arthritis Rheum 2004; 50: 3866-77.
143. Neumann E, Lefèvre S, Zimmermann B, et al. Migratory potential of rheumatoid arthritis synovial fibroblasts: additional perspectives. Cell Cycle 2010; 9: 2286-91.
144. Korb-Pap A, Stratis A, Mühlenberg K, et al. Early structural changes in cartilage and bone are required for the attachment and invasion of inflamed synovial tissue during destructive inflammatory arthritis. Ann Rheum Dis 2012; 71: 1004-11
145. Wicki A, Christofori G. The potential role of podoplain in tumour invasion. Br J Cancer 2007; 96: 1-5.
146. Ekwall AK, Eisler T, Anderberg C, et al. The tumour-associated glycoprotein podoplanin is expressed in fibroblast-like synoviocytes of the hyperplastic synovial lining layer in rheumatoid arthritis. Arthritis Res Ther 2011; 13: R40.
147. Wendling D, Prati C, Toussirot E, Herbein G. Targeting intracellular signaling pathways to treat rheumatoid arthritis: Pandora's box? Joint Bone Spine 2010; 77: 96-8.
148. Miossec P. Kinase inhibition in rheumatoid arthritis: a big advance? Lancet 2013; 381: 429-31.
149. van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012; 367: 508-19.
150. Fox DA. Kinase inhibition--a new approach to the treatment of rheumatoid arthritis. N Engl J Med 2012; 367: 565-7.
151. Maeshima K, Yamaoka K, Kubo S, et al. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-and interleukin-17 production by human CD4+ T cells. Arthritis Rheum 2012; 64: 1790-8.
152. Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013; 381: 451-60.
153. Rosengren S, Corr M, Firestein GS, Boyle DL. The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Ann Rheum Dis 2012; 71: 440-7.
154. Hammaker D, Boyle DL, Firestein GS. Synoviocyte innate immune responses: TANK-binding kinase-1 as a potential therapeutic target in rheumatoid arthritis. Rheumatology 2012; 51: 610-8.
155. Lee SI, Boyle DL, Berdeja A, Firestein GS. Regulation of inflammatory arthritis by the upstream kinase mitogen activated protein kinase kinase 7 in the c-Jun N-terminal kinase pathway. Arthritis Res Ther 2012; 14: R38.
156. Bartok B, Boyle DL, Liu Y, et al. PI3 kinase δ is a key regulator of synoviocyte function in rheumatoid arthritis. Am J Pathol 2012; 180: 1906-16.
157. Han MK, Kim JS, Park BH, et al. NF-kappaB-dependent lymphocyte hyperadhesiveness to synovial fibroblasts by hypoxia and reoxygenation: potential role in rheumatoid arthritis. J Leukoc Biol 2003; 73: 525-9.
158. Miranda-Carús ME, Balsa A, Benito-Miguel M, Pérez de Ayala C, Martín-Mola E. IL-15 and the initiation of cell contact-dependent synovial fibroblast-T lymphocyte cross-talk in rheumatoid arthritis: effect of methotrexate. J Immunol 2004; 173: 1463-76.
159. van Hamburg JP, Asmawidjaja PS, Davelaar N, et al. Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. Arthritis Rheum 2011; 63: 73-83
160. Armitage RJ, Macduff BM, Eisenman J, Paxton R, Grabstein KH. IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. J Immunol 1995; 154: 483-90.